PSMA-PET disease extent and overall survival in nmCRPC patients
Published : 22-06-2023 - Duration : 00:09:01 - Like : 2
Youtube : Download Convert to MP3
Description :
Prof. Boris A. Hadaschik (DE) talks about his presentation at ASCO23: Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study....

Related Videos :
![]() |
Understanding PSMA/PET, Axumin, MRI, Ultrasound | Ask a Prostate Expert, Mark Scholz, MD By: Prostate Cancer Research Institute |
![]() |
PSMA & Newly-Diagnosed #ProstateCancer | MarkScholzMD #AlexScholz #PCRI By: Prostate Cancer Research Institute |
![]() |
World Theranostics Presentation: TTV on F18-PSMA PET to monitor treatment response of 225Ac-PSMA-I&T By: Hermes Medical Solutions |
![]() |
2021: PSMA and Prostate Imaging | Dr. Thomas Hope | 2021 Moyad + Scholz Mid-Year Update | PCRI By: Prostate Cancer Research Institute |
![]() |
How PSMA Revolutionizes Staging for #prostatecancer | #markscholzmd | #PCRI By: Prostate Cancer Research Institute |
![]() |
Do we need the second PET (FDG) for patient selection? (including SUV for selection of PSMA therapy) By: ProsTIC TV |
![]() |
PSMA PET vs conventional imaging By: VJOncology |